Sharon Alroy-Preis Selected Research

BNT162 Vaccine

10/2022	Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
1/2022	Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
1/2022	Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
1/2022	Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
1/2022	Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
12/2021	Protection against Covid-19 by BNT162b2 Booster across Age Groups.
12/2021	Waning Immunity after the BNT162b2 Vaccine in Israel.
12/2021	Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
12/2021	Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study.
11/2021	The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sharon Alroy-Preis Research Topics

Disease

10	COVID-19 01/2022 - 01/2021
10	Infections 01/2022 - 01/2021
2	Myocarditis (Carditis) 10/2022 - 12/2021
1	Reinfection 01/2022
1	Asymptomatic Infections 01/2021
1	Hepatitis C 07/2014

Drug/Important Bio-Agent (IBA)

13	BNT162 VaccineIBA 10/2022 - 01/2021
10	VaccinesIBA 01/2022 - 01/2021
4	A-factor (Streptomyces)IBA 01/2022 - 10/2021
4	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
1	COVID-19 VaccinesIBA 01/2022
1	mRNA VaccinesIBA 12/2021
1	Neutralizing AntibodiesIBA 12/2021
1	EnzymesIBA 07/2014